Renal · Electrolyte Disorders
The facts most likely to be tested
The initial management for symptomatic hyperkalemia or EKG changes is intravenous calcium gluconate to stabilize the cardiac membrane.
The earliest EKG manifestation of hyperkalemia is peaked T waves, followed by PR interval prolongation and QRS complex widening.
Insulin with dextrose and beta-2 agonists (albuterol) are the primary intracellular shifting agents used to rapidly lower serum potassium.
Pseudohyperkalemia is a common laboratory artifact caused by hemolysis during difficult phlebotomy or thrombocytosis.
Potassium-sparing diuretics such as spironolactone, amiloride, and triamterene are classic pharmacological causes of hyperkalemia.
Type 4 Renal Tubular Acidosis (RTA), often associated with hyporeninemic hypoaldosteronism in diabetic patients, is a classic cause of non-anion gap metabolic acidosis with hyperkalemia.
Hemodialysis is the definitive treatment for severe, refractory hyperkalemia, particularly in patients with end-stage renal disease (ESRD).
Vignette unlocked
A 68-year-old male with a history of type 2 diabetes mellitus and chronic kidney disease presents to the emergency department with generalized weakness and palpitations. His medications include lisinopril and spironolactone. On physical exam, he is bradycardic. An EKG reveals peaked T waves and a widened QRS complex.
What is the most appropriate initial step in the management of this patient?
Intravenous calcium gluconate
The patient exhibits signs of cardiac toxicity from hyperkalemia; intravenous calcium is required immediately to stabilize the cardiac membrane and prevent life-threatening arrhythmias.
Full handout
High yield triage
Etiology / Epidemiology
Most common in CKD and patients on RAAS inhibitors. Often iatrogenic or due to pseudohyperkalemia.
Clinical Manifestations
Often asymptomatic until severe. Peaked T waves on ECG; sine wave pattern is a pre-arrest rhythm.
Diagnosis
Serum potassium > 5.0 mEq/L. ECG is the most critical immediate diagnostic tool.
Treatment
Stabilize membrane with Calcium Gluconate. Shift K+ with Insulin + Glucose. Do not delay.
Prognosis
Risk of fatal ventricular arrhythmias. Requires serial monitoring until levels < 5.0 mEq/L.
Full handout
Epidemiology & Etiology
Prevalence is highest in patients with Stage 4-5 CKD and those taking ACE inhibitors or ARBs. Pseudohyperkalemia from hemolysis during phlebotomy is a common diagnostic pitfall. Always consider adrenal insufficiency in unexplained cases.
Pertinent Anatomy
The distal convoluted tubule and collecting duct are the primary sites of potassium excretion. Impairment of the aldosterone-sensitive sodium pump directly limits renal potassium clearance.
Pathophysiology
Hyperkalemia decreases the resting membrane potential, initially increasing excitability before causing depolarization block. This leads to impaired cardiac conduction and skeletal muscle weakness. The heart is most sensitive to these shifts, manifesting as conduction delays.
Clinical Manifestations
Patients may present with muscle weakness, paralysis, or palpitations. ECG findings progress from peaked T waves to PR prolongation, QRS widening, and eventually a sine wave pattern. Cardiac arrest is the primary red flag.
Diagnosis
Serum potassium > 5.0 mEq/L confirms the diagnosis. ECG is the gold standard for assessing immediate cardiac risk. Always repeat the sample if hemolysis is suspected to rule out pseudohyperkalemia.
Treatment
First, stabilize the myocardium with Calcium Gluconate. Shift potassium intracellularly using Insulin + Glucose or Albuterol. Avoid calcium chloride in peripheral lines due to tissue necrosis risk. Use Loop diuretics or Kayexalate for total body potassium removal.
Prognosis
Untreated hyperkalemia leads to ventricular fibrillation and death. Patients require continuous cardiac monitoring until potassium levels normalize below 5.0 mEq/L.
Differential Diagnosis
Pseudohyperkalemia: normal ECG with high lab value
Adrenal Insufficiency: associated with hyponatremia
Tumor Lysis Syndrome: associated with hyperuricemia
Rhabdomyolysis: associated with elevated CK
Type 4 RTA: associated with non-anion gap metabolic acidosis